U.S. Markets closed
  • Crude Oil

    70.98
    +0.69 (+0.98%)
     
  • Gold

    1,763.70
    -0.10 (-0.01%)
     
  • Silver

    22.22
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1734
    +0.0007 (+0.0587%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3666
    +0.0007 (+0.0533%)
     
  • USD/JPY

    109.5700
    +0.1500 (+0.1371%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,067.59
    -66.79 (-5.89%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    29,898.57
    -601.48 (-1.97%)
     

Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate.

  • The companies in May started global trials to include more than 35,000 adults to test the candidate and hope to get approvals by the end of 2021.

  • Phase 2 interim results showed that the vaccine produces a robust immune response.

  • According to India's clinical trial registry, the Indian arm of the studies will enroll roughly 3,000 adults between the ages of 18 years and 55 years.

  • The assessment is expected to run for a year, and the first enrollment in India is already done.

  • GSK and Sanofi's vaccine candidate uses the same technology as one of Sanofi's seasonal influenza vaccines.

  • It will be coupled with an adjuvant made by GSK.

  • Sanofi also plans to test the vaccine as a booster, regardless of which shot a person may have received first.

  • Price Action: GSK shares are down 1.19% at $39.76, and SNY shares are down 0.43% at $50.99 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.